Salbutamol

IV (in the treatment of premature labour): Pre-existing or risk factors for ischaemic heart disease, gestational age <22 week, conditions in which prolongation of pregnancy is hazardous, intrauterine foetal death, known lethal congenital or lethal chromosomal malformation, pulmonary hypertension. Non-IV formulation is not indicated for use in uncomplicated premature labour or threatened abortion.

Patient with CV disease (e.g. arrythmia, coronary insufficiency, hypertension, heart failure), diabetes mellitus, glaucoma, hyperthyroidism, hypokalaemia, seizures. Renal impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor FEV₁ peak flow, and/or other pulmonary function tests; blood pressure, heart rate, CNS stimulation; serum glucose, K and creatinine; asthma symptoms; arterial or capillary blood gases if needed; lactate, and ECG (IV).

Significant: Hypersensitivity reactions (e.g. urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema), hypokalaemia (high doses). Cardiac disorders: Tachycardia, palpitations, chest pain. Rarely, cardiac arrythmias (e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles), myocardial ischaemia. Gastrointestinal disorders: Nausea, vomiting, mouth and throat irritation (inhalation). General disorders and administration site conditions: Weakness. Metabolism and nutrition disorders: Hyperglycaemia. Rarely, lactic acidosis (high doses). Musculoskeletal and connective tissue disorders: Muscle cramps. Nervous system disorders: Tremor, headache, dizziness, drowsiness, restlessness. Psychiatric disorders: Nervousness, irritability, insomnia. Respiratory, thoracic and mediastinal disorders: Pharyngitis, rhinitis, pulmonary oedema (parenteral). Vascular disorders: Peripheral vasodilation, flushing.
Potentially Fatal: Rarely, paradoxical bronchospasm.

Increased risk of hypokalaemia with corticosteroids, diuretics (e.g. loop, thiazide) and xanthines (e.g. theophylline). Increased vascular effects with MAOIs, tricyclic antidepressants (TCAs). May cause severe bronchospasm when used with β-blockers (e.g. propranolol). May decrease serum concentrations of digoxin.

Antiasthmatic & COPD Preparations / Drugs Acting on the Uterus

R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CC02 - salbutamol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.